21 Sep
by Vitaliy Dadalyan
Prostate cancer is the second-most common type of cancer in men worldwide, while ovarian cancer is the fifth most common cause of cancer death in Europe. The EMA recommendation follows positive regulatory updates for Lynparza, which AstraZeneca has developed with Merck & Co Inc as it faces competition from British rival GlaxoSmithKline on cancer drugs.
